Receipt of Palivizumab before Birth Hospitalization Discharge among Preterm Infants in the United States

American Journal of Perinatology

Volumn 32, Issue 11, 2015, Pages 1017-1023

  La Gamma, Edmund F ^a   Kumar, Veena R ^b   Wadhawan, Rajan ^c   Ye, Sherry ^b   Sifakis, Frangiscos ^b   Ycas, Joseph ^b   Ambrose, Christopher S ^b  

^a WESTCHESTER MEDICAL CENTER   (United States)

^b ASTRAZENECA   (United Kingdom)

^c FLORIDA HOSPITAL   (United States)

Author keywords

hepatitis B vaccine; palivizumab; preterm infants; respiratory syncytial virus; Vitamin K

Indexed keywords

PALIVIZUMAB; ANTIVIRUS AGENT; HEPATITIS B VACCINE; VITAMIN K GROUP;

CHILD HOSPITALIZATION; COHORT ANALYSIS; CONTROLLED STUDY; GESTATIONAL AGE; HOSPITAL DISCHARGE; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; MAJOR CLINICAL STUDY; NEWBORN; PREMATURITY; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SEASON; UNITED STATES; FACTUAL DATABASE; FEMALE; HOSPITALIZATION; INFANT; MALE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA;

ANTIVIRAL AGENTS; DATABASES, FACTUAL; FEMALE; GESTATIONAL AGE; HEPATITIS B VACCINES; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; LOGISTIC MODELS; MALE; PALIVIZUMAB; PATIENT DISCHARGE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RETROSPECTIVE STUDIES; UNITED STATES; VITAMIN K;

EID: 84941600369     PISSN: 07351631     EISSN: 10988785     Source Type: Journal    
DOI: 10.1055/s-0034-1543951     Document Type: Review

References (19)

1. Horn S. D., Smout R. J. Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes. J Pediatr: 2003; 143 (5, Suppl): S133 S141
2. Langley G. F., Anderson L. J. Epidemiology and prevention of respiratory syncytial virus infections among infants and young children. Pediatr Infect Dis J: 2011; 30 6 510 517
3. Bont L., Kimpen J. L. Immunological mechanisms of severe respiratory syncytial virus bronchiolitis. Intensive Care Med: 2002; 28 5 616 621
4. Ballow M., Cates K. L., Rowe J. C., Goetz C., Desbonnet C. Development of the immune system in very low birth weight (less than 1500 g) premature infants: concentrations of plasma immunoglobulins and patterns of infections. Pediatr Res: 1986; 20 9 899 904
5. The IMpact-RSV Study Group Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics: 1998; 102 3 Pt 1 531 537
6. Blanken M. O., Rovers M. M., Molenaar J. M., et al. Dutch RSV Neonatal Network. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med: 2013; 368 19 1791 1799
7. Palivizumab. Full Prescribing Information. MedImmune Gaithersburg, MD: 2014
8. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics: 1998; 102 5 1211 1216
9. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics: 2003; 112 6 Pt 1 1442 1446
10. American Academy of Pediatrics Respiratory syncytial virus. In: Pickering L. K., Baker C. J., Long S. S., McMillan J. A. eds. Red Book: 2006 Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL American Academy of Pediatrics: 2006; 560 566
11. American Academy of Pediatrics Respiratory syncytial virus. In: Pickering L. K., Baker C. J., Kimberlin D. W., Long S. S. eds. Red Book: 2009 Report of the Committee on Infectious Diseases. 28th ed. Elk Grove Village, IL American Academy of Pediatrics: 2009; 560 569
12. Speer M. E., Boron M., McLaurin K., Cohen A., Rankin M., Groothuis J. Palivizumab outcomes registry 2000 to 2004: delayed prophylaxis in children at high risk of respiratory syncytial virus (RSV) disease. Neonatology Today: 2007; 2 4 1 5
13. Palivizumab distribution network Data on File. MedImmune Gaithersburg, MD: 2012; -2013
14. Golombek S. G., Berning F., Lagamma E. F. Compliance with prophylaxis for respiratory syncytial virus infection in a home setting. Pediatr Infect Dis J: 2004; 23 4 318 322
15. Centers for Disease Control and Prevention (CDC) National, state, and local area vaccination coverage among children aged 19-35 months - United States, 2008. MMWR Morb Mortal Wkly Rep: 2009; 58 33 921 926
16. 2011/2012 Medicaid RSV infection prophylaxis update Available at: http://dhhs.ne.gov/medicaid/Documents/pb1152.pdf. Accessed May 6, 2014
17. Health services provider manual: policies and procedures. Available at: http://www.scdhhs.gov/internet/pdf/manuals/Hospital/Section%202.pdf. Accessed May 6, 2014
18. American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics: 2014; 134 2 415 420
19. Mackun P., Wilson S. Population distribution and change: 2000 to 2010. Available at: http://www.census.gov/prod/cen2010/briefs/c2010br-01.pdf. Accessed May 6, 2014